|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IRAK3 |
Gene summary for IRAK3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IRAK3 | Gene ID | 11213 |
| Gene name | interleukin 1 receptor associated kinase 3 | |
| Gene Alias | ASRT5 | |
| Cytomap | 12q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9Y616 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11213 | IRAK3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.13e-16 | 7.88e-01 | -0.1808 |
| 11213 | IRAK3 | HTA11_2951_2000001011 | Human | Colorectum | AD | 6.30e-03 | 4.13e-01 | 0.0216 |
| 11213 | IRAK3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.04e-03 | 2.77e-01 | -0.0811 |
| 11213 | IRAK3 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.19e-07 | 3.39e-01 | -0.1088 |
| 11213 | IRAK3 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.68e-03 | 1.25e-01 | -0.1954 |
| 11213 | IRAK3 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.69e-26 | 8.21e-01 | -0.1207 |
| 11213 | IRAK3 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.07e-08 | 3.78e-01 | -0.1526 |
| 11213 | IRAK3 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.26e-09 | 3.63e-01 | -0.1464 |
| 11213 | IRAK3 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.64e-11 | 3.03e-01 | -0.1001 |
| 11213 | IRAK3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.06e-12 | 4.76e-01 | -0.059 |
| 11213 | IRAK3 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.31e-03 | 6.70e-01 | 0.3487 |
| 11213 | IRAK3 | AEH-subject4 | Human | Endometrium | AEH | 2.81e-07 | 3.54e-01 | -0.2657 |
| 11213 | IRAK3 | RNA-P3T-P3T-1 | Human | Lung | IAC | 2.55e-10 | 8.39e-01 | 0.1829 |
| 11213 | IRAK3 | RNA-P3T-P3T-2 | Human | Lung | IAC | 6.02e-10 | 7.79e-01 | 0.1835 |
| 11213 | IRAK3 | RNA-P3T-P3T-4 | Human | Lung | IAC | 1.37e-15 | 8.86e-01 | 0.1859 |
| 11213 | IRAK3 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.67e-03 | 2.45e-01 | -0.0166 |
| 11213 | IRAK3 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.09e-05 | 3.19e-01 | -0.0132 |
| 11213 | IRAK3 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.28e-06 | 2.83e-01 | -0.013 |
| 11213 | IRAK3 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.04e-05 | 2.94e-01 | -0.0121 |
| 11213 | IRAK3 | ATC13 | Human | Thyroid | ATC | 3.23e-51 | 8.52e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0042177 | Colorectum | AD | negative regulation of protein catabolic process | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
| GO:0032984 | Colorectum | AD | protein-containing complex disassembly | 81/3918 | 224/18723 | 9.41e-08 | 4.65e-06 | 81 |
| GO:0010563 | Colorectum | AD | negative regulation of phosphorus metabolic process | 130/3918 | 442/18723 | 1.26e-05 | 2.76e-04 | 130 |
| GO:0045936 | Colorectum | AD | negative regulation of phosphate metabolic process | 129/3918 | 441/18723 | 1.81e-05 | 3.76e-04 | 129 |
| GO:0051348 | Colorectum | AD | negative regulation of transferase activity | 85/3918 | 268/18723 | 2.07e-05 | 4.19e-04 | 85 |
| GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
| GO:0042326 | Colorectum | AD | negative regulation of phosphorylation | 112/3918 | 385/18723 | 8.02e-05 | 1.27e-03 | 112 |
| GO:0001933 | Colorectum | AD | negative regulation of protein phosphorylation | 101/3918 | 342/18723 | 9.39e-05 | 1.42e-03 | 101 |
| GO:0043409 | Colorectum | AD | negative regulation of MAPK cascade | 57/3918 | 180/18723 | 4.61e-04 | 5.14e-03 | 57 |
| GO:0006469 | Colorectum | AD | negative regulation of protein kinase activity | 65/3918 | 212/18723 | 5.21e-04 | 5.62e-03 | 65 |
| GO:0033673 | Colorectum | AD | negative regulation of kinase activity | 71/3918 | 237/18723 | 6.18e-04 | 6.47e-03 | 71 |
| GO:0043244 | Colorectum | AD | regulation of protein-containing complex disassembly | 41/3918 | 121/18723 | 6.22e-04 | 6.48e-03 | 41 |
| GO:0043242 | Colorectum | AD | negative regulation of protein-containing complex disassembly | 29/3918 | 82/18723 | 1.76e-03 | 1.45e-02 | 29 |
| GO:0071900 | Colorectum | AD | regulation of protein serine/threonine kinase activity | 98/3918 | 359/18723 | 2.18e-03 | 1.73e-02 | 98 |
| GO:0051091 | Colorectum | AD | positive regulation of DNA-binding transcription factor activity | 73/3918 | 260/18723 | 3.52e-03 | 2.54e-02 | 73 |
| GO:00421761 | Colorectum | SER | regulation of protein catabolic process | 126/2897 | 391/18723 | 5.33e-17 | 2.52e-14 | 126 |
| GO:00224111 | Colorectum | SER | cellular component disassembly | 114/2897 | 443/18723 | 1.17e-08 | 9.59e-07 | 114 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
| hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
| hsa047222 | Colorectum | SER | Neurotrophin signaling pathway | 35/1580 | 119/8465 | 2.80e-03 | 2.02e-02 | 1.47e-02 | 35 |
| hsa047223 | Colorectum | SER | Neurotrophin signaling pathway | 35/1580 | 119/8465 | 2.80e-03 | 2.02e-02 | 1.47e-02 | 35 |
| hsa0472216 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
| hsa0472217 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
| hsa0472212 | Lung | IAC | Neurotrophin signaling pathway | 29/1053 | 119/8465 | 2.34e-04 | 2.54e-03 | 1.68e-03 | 29 |
| hsa0472213 | Lung | IAC | Neurotrophin signaling pathway | 29/1053 | 119/8465 | 2.34e-04 | 2.54e-03 | 1.68e-03 | 29 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IRAK3 | SNV | Missense_Mutation | c.1312N>A | p.Glu438Lys | p.E438K | Q9Y616 | protein_coding | tolerated(0.09) | probably_damaging(0.941) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| IRAK3 | SNV | Missense_Mutation | novel | c.1330N>A | p.Glu444Lys | p.E444K | Q9Y616 | protein_coding | deleterious(0.01) | possibly_damaging(0.679) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| IRAK3 | SNV | Missense_Mutation | c.1408T>G | p.Phe470Val | p.F470V | Q9Y616 | protein_coding | tolerated(0.05) | possibly_damaging(0.471) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| IRAK3 | SNV | Missense_Mutation | novel | c.521N>T | p.Gly174Val | p.G174V | Q9Y616 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IRAK3 | SNV | Missense_Mutation | novel | c.1257N>G | p.Phe419Leu | p.F419L | Q9Y616 | protein_coding | tolerated(1) | benign(0.031) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| IRAK3 | SNV | Missense_Mutation | novel | c.632C>T | p.Ser211Phe | p.S211F | Q9Y616 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| IRAK3 | SNV | Missense_Mutation | c.466N>G | p.Gln156Glu | p.Q156E | Q9Y616 | protein_coding | tolerated(0.47) | benign(0.057) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IRAK3 | SNV | Missense_Mutation | c.1226N>T | p.Pro409Leu | p.P409L | Q9Y616 | protein_coding | tolerated(0.07) | probably_damaging(0.986) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IRAK3 | deletion | Frame_Shift_Del | c.592delN | p.Met200CysfsTer26 | p.M200Cfs*26 | Q9Y616 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |||
| IRAK3 | SNV | Missense_Mutation | novel | c.591N>T | p.Glu197Asp | p.E197D | Q9Y616 | protein_coding | tolerated(0.25) | possibly_damaging(0.735) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11213 | IRAK3 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565893 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |